Research & Development

Seismic raises $101m to advance two drug programmes to clinic

Seismic Therapeutic has raised $101m in Series A financing led by Lightspeed Venture Partners to advance its first two lead drug programmes to the clinic.

Healx secures option to license rights from Ovid to develop gaboxadol

Healx, an AI-powered, technology company involved in the next generation of drug discovery, has secured an exclusive option to license rights to develop and commercialize gaboxadol from biopharmaceutical company Ovid Therapeutics.

Mersana, Janssen Biotech partner to discover new ADC product candidates

Mersana Therapeutics and Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a research collaboration and license agreement for the discovery of new antibody-drug conjugates (ADCs) for three targets.

Alvotech, BiosanaPharma partner to develop biosimilar for Xolair

Biopharmaceutical company Alvotech and BiosanaPharma have signed an exclusive global licensing agreement for the co-development of a proposed biosimilar, AVT23 (also called BP001), to Xolair (omalizumab).

Ocugen to buy Liminal’s vaccine manufacturing facility in Canada

US-based Ocugen has signed a letter of intent (LOI) to acquire Liminal Biosciences’ manufacturing site located in Belleville, Ontario, Canada, for an undisclosed sum.

Twist Bioscience, Artisan Development Labs partner to discover cell therapies

Twist Bioscience has teamed up with Artisan Development Labs to discover new antibodies against five undisclosed targets.

Prellis, Bristol Myers Squibb collaborate to discover antibodies

Prellis Biologics and Bristol Myers Squibb have signed a multi-target collaboration and license agreement to discover antibodies.

Lantern Pharma and NCI expand oncology partnership

Lantern Pharma and the US National Institutes of Health unit National Cancer Institute’s (NCI) Developmental Therapeutics Branch (DTB) have announced the extension of their oncology collaboration for first in human clinical trials for drug candidates LP-184 and LP-284.

Absci and Merck collaborate to develop new enzymes

Drug and target discovery company Absci has signed a research collaboration with Merck to produce new enzymes.